Medicare Bill Contains Significant Changes for Drug Manufacturers

The new Medicare bill affects pricing and coverage, revises payment formula, and clarifies generic patent issues.

Related Content:

Regulatory WatchPharmaceutical Technology-01-02-2004

Advancing Global Collaboration for Drug Testing, Regulation, and Manufacturing

FDA In Limbo as User Fee Renewal Stuck on Capitol Hill

FDA Joins Effort to Curb Drug Patent Abuses